SYRA3 COST Action – Microbeam radiation therapy: Roots and prospects

Bravin, A.; Olko, P.; Schültke, Elisabeth; Wilkens, Jan J.

doi:10.1016/j.ejmp.2015.06.002

Cited by 18 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the state of the art, synchrotron stereotactic radiotherapy (SSRT) (Renier et al, 2008;Brä uer-Krisch et al, 2015), minibeam radiation therapy (MBRT) (Deman et al, 2012) and microbeam radiation therapy (MRT) (Crosbie et al, 2013;Bravin et al, 2015;Grotzer et al, 2015;Poole et al, 2017) are the radiotherapy techniques under investigation at several synchrotron radiation (SR) facilities. These include the Australian Synchrotron (AS) in Melbourne, Australia, and the European Synchrotron Radiation Facility (ESRF) in Grenoble, France, having active programs for developing clinical applications in radiotherapy.…”

Section: Radiotherapy With Synchrotron Radiationmentioning

confidence: 99%

Synchrotron radiation external beam rotational radiotherapy of breast cancer: proof of principle

Lillo

Mettivier

Castriconi

et al. 2018

J Synchrotron Radiat

View full text Add to dashboard Cite

The principle of rotational summation of the absorbed dose for breast cancer treatment with orthovoltage X-ray beams was proposed by J. Boone in 2012. Here, use of X-ray synchrotron radiation for image guided external beam rotational radiotherapy treatment of breast cancer is proposed. Tumor irradiation occurs with the patient in the prone position hosted on a rotating bed, with her breast hanging from a hole in the bed, which rotates around a vertical axis passing through the tumor site. Horizontal collimation of the X-ray beam provides for whole breast or partial breast irradiation, while vertical translation of the bed and successive rotations allow for irradiation of the full tumor volume, with dose rates which permit also hypofractionated treatments. In this work, which follows a previous preliminary report, results are shown of a full series of measurements on polyethylene and acrylic cylindrical phantoms carried out at the Australian Synchrotron, confirmed by Geant4 Monte Carlo simulations, intended to demonstrate the proof of principle of the technique. Dose measurements were carried out with calibrated ion chambers, radiochromic films and thermoluminescence dosimeters. The photon energy investigated was 60 keV. Image guidance may occur with the transmitted beam for contrast-enhanced breast computed tomography. For a horizontal beam collimation of 1.5 cm and rotation around the central axis of a 14 cm-diameter polyethylene phantom, a periphery-to-center dose ratio of 14% was measured. The simulations showed that under the same conditions the dose ratio decreases with increasing photon energy down to 10% at 175 keV. These values are comparable with those achievable with conventional megavoltage radiotherapy of breast cancer with a medical linear accelerator. Dose painting was demonstrated with two off-center `cancer foci' with 1.3 Gy and 0.6 Gy target doses. The use of a radiosensitizing agent for dose enhancement is foreseen.

show abstract

Section: Radiotherapy With Synchrotron Radiationmentioning

confidence: 99%

Synchrotron radiation external beam rotational radiotherapy of breast cancer: proof of principle

Lillo

Mettivier

Castriconi

et al. 2018

J Synchrotron Radiat

View full text Add to dashboard Cite

show abstract

“…Amongst other treatment methods, such as surgery and chemotherapy, the use of radiation in the treatment of cancer remains the most prominent and successful modality [1]. The sensitive treatment of brain tumours (such as inoperable gliomas and gliosarcomas), with wide, and unsegmented radiotherapeutic beams, impart unavoidable yet clinically unacceptable damage to vital central nervous system (CNS) tissues [2,3]. Microbeam radiation therapy (MRT) may provide a solution to this challenge.…”

Section: Introductionmentioning

confidence: 99%

“…MRT involves the application of an array of spatially fractionated microbeams sourced from third generation synchrotrons, with beam widths ranging from 25 to 75 µm, and a pitch of 200-400 µm [2][3][4][5][6][7][8][9][10][11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Optimizing dose enhancement with Ta 2 O 5 nanoparticles for synchrotron microbeam activated radiation therapy

et al. 2016

View full text Add to dashboard Cite

Microbeam Radiation Therapy (MRT) exploits tumour selectivity and normal tissue sparing with spatially fractionated kilovoltage X-ray microbeams through the dose volume effect. Experimental measurements with Ta 2 O 5 nanoparticles (NPs) in 9L gliosarcoma treated with MRT at the Australian Synchrotron, increased the treatment efficiency. Ta 2 O 5 NPs were observed to form shells around cell nuclei which may be the reason for their efficiency in MRT. In this article, our experimental observation of NP shell formation is the basis of a Geant4 radiation transport study to characterise dose enhancement by Ta 2 O 5 NPs in MRT. Our study showed that NP shells enhance the physical dose depending microbeam energy and their location relative to a single microbeam. For monochromatic microbeam energies below ∼70 keV, NP shells show highly localised dose enhancement due to the short range of associated secondary electrons. Low microbeam energies indicate better targeted treatment by allowing higher microbeam doses to be administered to tumours and better exploit the spatial fractionation related selectivity observed with MRT. For microbeam energies above ∼100 keV, NP shells extend the physical dose enhancement due to longer-range secondary electrons. Again, with NPs selectively internalised, the local effectiveness of MRT is expected to increase in the tumour. Dose enhancement produced by the shell aggregate varied more significantly in the cell population, depending on its location, when compared to a homogeneous NP distribution. These combined simulation and experimental data provide first evidence for optimising MRT through the incorporation of newly observed Ta 2 O 5 NP distributions within 9L cancer cells. Disciplines Engineering | Science and Technology Studies Publication DetailsEngels, E., Corde, S., McKinnon, S., Incerti, S., Konstantinov, K., Rozenfeld, A., Tehei, M., . Optimizing dose enhancement with Ta2O5 nanoparticles for synchrotron microbeam activated radiation therapy. Physica Medica: an international journal devoted to the applications of physics to medicine and biology, 32 (12)

show abstract

“…In a number of cell and animal studies, healthy tissue has been shown to be resilient to MRT unlike tumour tissue, which is susceptible to high doses (Bouchet et al, 2012Anderson et al, 2014;Bronnimann et al, 2016). It has been hypothesized that this sparing of healthy tissue can allow patients with malignant central nervous system tumours, who currently have no safe therapies available to them, to be treated with MRT (Bravin et al, 2015;Grotzer et al, 2015). The high dose rate of MRT allows the required quantity to be delivered to the target quickly and with minimal dose blurring.…”

Section: Introductionmentioning

confidence: 99%

Synchrotron X-ray microbeam dosimetry with a 20 micrometre resolution scintillator fibre-optic dosimeter

Archer¹,

Li²,

Petasecca³

et al. 2018

J Synchrotron Rad

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide. External beam radiation therapy is one of the most important modalities for the treatment of cancers. Synchrotron microbeam radiation therapy (MRT) is a novel pre-clinical therapy that uses highly spatially fractionated X-ray beams to target tumours, allowing doses much higher than conventional radiotherapies to be delivered. A dosimeter with a high spatial resolution is required to provide the appropriate quality assurance for MRT. This work presents a plastic scintillator fibre optic dosimeter with a one-dimensional spatial resolution of 20 µm, an improvement on the dosimeter with a resolution of 50 µm that was demonstrated in previous work. The ability of this probe to resolve microbeams of width 50 µm has been demonstrated. The major limitations of this method were identified, most notably the low-light signal resulting from the small sensitive volume, which made valley dose measurements very challenging. A titanium-based reflective paint was used as a coating on the probe to improve the light collection, but a possible effect of the high-Z material on the probes water-equivalence has been identified. The effect of the reflective paint was a 28.5 ± 4.6% increase in the total light collected; it did not affect the shape of the depth-dose profile, nor did it explain an over-response observed when used to probe at low depths, when compared with an ionization chamber. With improvements to the data acquisition, this probe design has the potential to provide a water-equivalent, inexpensive dosimetry tool for MRT.

show abstract

SYRA3 COST Action – Microbeam radiation therapy: Roots and prospects

Cited by 18 publications

References 15 publications

Synchrotron radiation external beam rotational radiotherapy of breast cancer: proof of principle

Synchrotron radiation external beam rotational radiotherapy of breast cancer: proof of principle

Optimizing dose enhancement with Ta 2 O 5 nanoparticles for synchrotron microbeam activated radiation therapy

Synchrotron X-ray microbeam dosimetry with a 20 micrometre resolution scintillator fibre-optic dosimeter

Contact Info

Product

Resources

About